Omar Abdul-Jawad Altisent et al. JCIN 2016;9:

Slides:

Advertisements

Similar presentations

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.

Advertisements

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Anticoagulation of Bioprosthetic Aortic Valves.

From: Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Implantation J Am Coll.

Figure 1 Ischaemic endpoints

Figure 1 Flow chart diagram of high-risk group AF patients

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Oral Anticoagulation and Preventing Stent Thrombosis

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Glenn N. Levine et al. JACC 2016;68:

When Is Adding Aspirin to NOACs Worth the Risk?

PAD Patients vs Post-ACS Patients:

Nat. Rev. Cardiol. doi: /nrcardio

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Noriko Kikuchi et al. JACEP 2016;2:

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

AF and PCI in Practice.

Relative risk of major events with atenolol vs placebo

Belinda Gray et al. JCHF 2013;1:

Ryoji Nagoshi et al. JCIN 2016;9:e107-e109

David F. Katz et al. JACEP 2016;j.jacep

Muhammad Shahreyar et al. JACEP 2016;j.jacep

Giuseppe Boriani et al. JACEP 2016;2:

Mohit K. Turagam et al. JACEP 2017;3:

John A. Bittl et al. JACC 2016;68:

Ashraf Hamdan et al. JCIN 2015;8:

Mintu P. Turakhia et al. JACEP 2016;2:

Svend A. Mortensen et al. JCHF 2014;2:

Yoshitaka Kimura et al. JACEP 2016;2:

Kenshi Hayashi et al. JACEP 2016;2:

David F. Katz et al. JACEP 2017;3:20-28

Toshiaki Toyota et al. JCIN 2017;10:27-37

Roberta Rossini et al. JCIN 2018;11:

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

Kensuke Nishimiya et al. JCIN 2016;9:

Seung-Yul Lee et al. JCIN 2018;j.jcin

Björn Redfors et al. JACEP 2017;j.jacep

Jose C. Pachon M. et al. JACEP 2015;1:

Michael S. Kim et al. JCIN 2009;2:81-90

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Giuseppe Gargiulo et al. JACC 2018;71:

Figure 2 Kaplan-Meier survival graphs for 10-year risks of overall and post-90-day recurrent ischemic stroke (IS) and death Kaplan-Meier survival graphs.

Charanjit S. Rihal et al. JCIN 2012;5:

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Davide Capodanno et al. JCIN 2009;2:

Nils P. Johnson et al. JCIN 2015;8:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Ryan R. Reeves et al. JCIN 2015;8:

Christian Madelaire et al. JCHF 2018;6:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Maxime Berthelot-Richer et al. JIMG 2016;9:

Orly Vardeny et al. JCHF 2016;4:

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

Stefan Toggweiler et al. JCIN 2016;9:

Daniele Muser et al. JACEP 2017;j.jacep

Metaregression showing the relationship between bleeding and antiplatelet strategy. Metaregression showing the relationship between bleeding and antiplatelet.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Presentation transcript:

Omar Abdul-Jawad Altisent et al. JCIN 2016;9:1706-1717 Kaplan-Meier Curves at 1-Year Follow-Up for Ischemic Events, Bleeding Events, and Death, According to Antithrombotic Therapy (Warfarin Alone vs. Warfarin Plus Dual Antiplatelet Therapy) Kaplan-Meier curves at 1-year follow-up for (A) the combined endpoint of stroke, MI, or cardiovascular death; (B) Valve Academic Research Consortium-2 major or life-threatening bleeding; and (C) the combined endpoint of stroke, MI, or any type of bleeding according to the antithrombotic strategy used (warfarin alone vs. dual antiplatelet therapy). ASA = aspirin; other abbreviations as in Figure 1. Omar Abdul-Jawad Altisent et al. JCIN 2016;9:1706-1717 American College of Cardiology Foundation